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Summary 
The  first  immunoglobulin V-like  domain  of CD4  contains  the  binding  site  for  human 
immunodeficiency  virus gp120. Guided by the atomic structure of a two-domain CD4 fragment, 
we have examined gp120 interaction with informative CD4 mutants, both by equilibrium and 
kinetic analysis. The binding site on CD4 appears to be a surface region of about 900 A  2 on 
the C" edge of the domain. It contains an exposed hydrophobic residue, Phe43, on the C" strand 
and four positively charged residues, Lys29, Lys35, LYS46, and Arg59, on the C, C', C", and 
D strands, respectivdy. Replacement of Phe43 with Ala or Ile reduces affinity for gp120 by more 
than 500-fold; Tyr, Trp, and Leu substitutions have smaller effects. The four positively charged 
side chains each make significant  contributions (7-50-fold). This CD4 site may dock into a conserved 
hydrophobic pocket bordered by several negatively charged residues in gpi20. Class II major 
histocompatibility complex binding includes the same region on CD4; this overlap needs to 
be considered in the design of inhibitors of the CD4-gp120  interaction. 
T 
he CD4 transmembrane glycoprotein participates in key 
steps of thymocyte differentiation (1-3) and T lympho- 
cyte activation  (4-9) by interacting with nonpolymorphic 
regions of class II MHC molecules (10--12). It is expressed 
on most thymocytes (1) and a subset of T lymphocytes, in- 
cluding helper T cells and class II MHC-specific  cytotoxic 
T  cells (5-7,  D,  14). CD4 in humans is also the receptor 
for HIV (15-18). It is required for viral attachment and sub- 
sequent entry into ceils (19), and these functions account for 
HIV T cell tropism. The virus binds through a contact made 
by the gp120 component of its envelope glycoprotein (20). 
The binding of gp120 to CD4 has been implicated in the 
cellular depletion of CD4 + lymphocytes in AIDS (21-24), 
and circulating free gp120 is thought to interfere with normal 
immune function (12, 25). The central role of the CD4-gp120 
interaction in the pathogenesis  of AIDS justifies  a detailed 
analysis in molecular terms, and inhibition of that interac- 
tion is also an attractive  target for antiviral intervention. 
The extracellular part of CD4 contains  four Ig-like do= 
mains (26). The gp120 binding site lies in the most NH2 
terminal of these domains (27, 28). A number of studies era- 
ploying escape mutants (29), insertion mutagenesis (30), ho- 
mology scanning mutagenesis (12, 28, 31), and alanine scan- 
ning mutagenesis (32) have helped to restrict the binding site 
to a segment surrounding the region homologous to the 
CDR2 of an Ig V domain. 
The atomic structure of a fragment containing the first 
two domains of CD4 has been determined by x-ray crystal- 
lography (33, 34). The first domain contains two antiparallel 
sheets, as predicted by its Ig V homology. The mutations 
that affect gp120 binding lie mostly in the antiparalld strands, 
denoted C' and C", that form a ridge at one edge of the do- 
main as well as in the adjacent D  strand.  The C'C" loop 
is longer than the CDR2 loop of a typical Ig V domain, 
and it projects prominently from the surface of the molecule 
(33). 
The experiments  reported here were designed to obtain 
quantitative measurements of the contributions made by in- 
dividual amino acid side chains to gp120 binding. Informed 
by the atomic structure, we have substituted exposed and bu- 
ried residues in domain 1 of CD4 and we have analyzed these 
mutants, in which only local perturbations of structure occur. 
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at 37~  where equilibrium can be reached,  rather than at 
the lower temperature used in many previous reports (12, 28, 
30-32). We can therefore distinguish effects on the equilib- 
rium binding constant from effects on the association rate 
constant. We have also measured the kinetics of association 
and dissociation. Our results show that the key binding sur- 
face for gp120 contains an exposed hydrophobic residue with 
spatially adjacent, positively charged amino acids. The struc- 
ture of the hydrophobic side chain and the positive charges 
on the surrounding residues are both important for the gpl20 
interaction. These features are critical for the interaction with 
gp120 from different HIV strains, despite substantial sequence 
differences between them. 
Materials and Methods 
Antibodies and Cells.  CD4 mAbs 19Thy5D7 and 18T3A9 have 
been described  previously  (7). 1LFT4  was provided  by Dr. G. Janossy 
(Royal Free Hospital, London), and BL410T4 and VIT4 were ob- 
tained through the Third Leukocyte  Typing Workshop. Anti-HIV-I 
gp120 mAb specific  for HIVIIIB gp120 was purchased from New 
England Nuclear-DuPont (Wilmington, DE). mAb F59.1 reactive 
with gp120 from strain SF2 was obtained from Repligen (Cam- 
bridge, MA). tLecomhinant  gp120 from HIV strains IIIB and SF2 
were provided by the AIDS program, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health (Rockville, 
MD) and Chiron Inc. (Emeryville, CA), respectively. OKT4 hy- 
bridomas ceils were obtained from American Type Culture Collec- 
tion (gockville, MD). MA5.8 cells were the kind gift of  J. Ash- 
well (NIH).  PBL were prepared from whole blood by gradient 
centrifugation employing FicoLl-Hypaque  (Pharmacia Fine Chem- 
icals, Piscataway,  NJ). Culture medium was tLPMI (Gibco Labora- 
tories, Grand Island, NY) containing 10% FCS (Sigma Chemical 
Co., St. Louis, MO), 200 mM glutamine (Gibco Laboratories), 
100 mM Na-pyruvate  (Gibco Laboratories), penicillin/streptomycin 
(Gibco Laboratories),  and 5 x  10 -s M 2-ME (Sigma  Chemical  Co.). 
Site-directed Mutagenesis and Transfection.  A transmembrane ver- 
sion of CD4 that has been previously subdoned into MDmp18 
(35) was used as temphte for oligonudeotide-directed mutagen- 
esis using a mutagenesis  kit (Amersham Corp., Arlington Heights, 
IL). Single-stranded  DNA was prepared and mutagenesis  performed 
according to the manufacturer's recommendations. Oligonucleo- 
tides encoding single amino acid substitutions (18-22 bases) were 
synthesized  using standard  cyanoethyl  phusphoramodite  chemistry. 
The presence of  mutations was confirmed  by sequencing  MDmplS- 
CD4 constructs. Mutant CD4 inserts were excised  with XbaI and 
subdoned into the XbaI side of the vector Pink-2 (36). Pink-2- 
CD4 plasmid  DNA was purified  using a plasmid  kit (Qiagen, Chats- 
worth, CA) and was sequenced using double-stranded DNA as 
template in order to confirm each mutation in the expression  vector. 
All mutations were verified  by sequencing the DNA encoding do- 
main 1. Mutant T45A contained a second point mutation, I24T. 
However, since an independent I24T mutation did not affect HIV 
binding (35), we consider the effect of this mutant to be due to 
the alteration of residue 45. Mouse T hybridoma ceil line MA5.8 
(2  x  107 cells) was  transfected with  15  /zg linearized (XmnI 
digested) plasmid DNA by electroporation (Cell Porator; 300 V, 
1,100 ~tF; Bethesda  Research  Laboratories,  Gaithersburg,  MD). Cells 
were plated at 3  x  10  s cdls/ml in culture medium in 24-well 
plates. At 48 h posttransfection, the medium was replaced with 
culture medium containing 1 mg/ml G418 (Gibco Laboratories). 
Growing colonies were transferred, expanded in medium with 0.5 
mg/ml G418 and subsequently tested for CD4 expression by im- 
munofluorescence using OKT4. 
gpl20 Binding.  For equilibrium binding assays, 2  x  10  s cells 
in 4-ml tubes and 0.1 ml culture medium containing 0.002% Na- 
Azide were incubated with different concentrations of gp120 at 
37~  in 5% CO2-humiditied atmosphere for 8-12 h. Ceils were 
washed and processed for immunofluorescence.  In on-rate experi- 
ments ceils were incubated as above, but gp120 (about threefold 
Ka) was added at different time points. All samples were processed 
together for immunofluorescence.  In off-rate  experiments, 3  x  106 
cells were incubated in 0.5 ml culture medium containing 0.002% 
Na-Azide and saturating concentrations ofgpl20 at 37~  for I h. 
Samples were washed twice and incubated at 4~  Aliquots of  3 x 
10  s cells (0.1 ml) were transferred to  1 ml prewarmed 07~ 
waterbath) medium and incubated for the time period indicated. 
Samples  were subsequently  washed and  processed  for  im- 
munofluorescence  at 4~  Identical  kinetics  for the off-reaction  were 
observed when cells preincubated with gp120 and subsequently 
washed were incubated at 37~  with or without 100 nM soluble 
CD4. 
Immunofluorescence.  Call-bound gp120 was determined by in- 
direct immunofluorescence.  Cells were incubated with saturating 
amounts of  anti-gp120 mAb (anti-HIVIIIB mAb, 0.1/~g/ml; F59.1, 
10/~g/ml) in 0.1 ml RPMI containing 2% FCS at 4~  for 30 rain. 
A PITC-hbded goat anti-mouse Ab (1:100; Caltag, San Francisco, 
CA) was used as second-step reagent, and cell-bound fluorescence 
was determined using a FACS  |  analyzer (Becton Dickinson & Co., 
Mountain View, CA). Dead cells were excluded after addition of 
propidium iodide. Linear equivalents of mean fluorescence were 
obtained using the Concert 30 program (Becton  Dickinson & Co.). 
Immunofluorescence using CD4 mAbs aimed at mapping mAb 
binding sites was performed similarly, except that two different 
nonsaturating CD4 mAb concentrations yielding between 50 and 
90% of maximum fluorescence  against wild type (wt)-CD4 were 
used. Nonsaturating concentrations were used in order to max- 
imize sensitivity. 
Calculations.  The fraction of bound gp120 was determined ac- 
cording to  the formula: f  =  FL-FL,~/FLm~ -  FLn~, where 
FLm~ *, anti-gp120 fluorescence  at saturation or at the beginning 
(t =~ 0) of an off-rate experiment, FL  **  anti-gp120 fluorescence 
at a given gp120 concentration or at a given time point, and FLy 
=  anti-gp120 fluorescence  in the absence of gp120, respectively. 
We assume that FLm~ -  FLy represents the concentration of 
CD4-gp120 complex at equilibrium and that gp120 concentrations 
are always  in excess over the CD4 concentrations. Thus, the mass 
action law was transformed  into FL -  FLy ~- [gp120~ x  (FLm~ 
-  FL~)]/(Ka +  gp120tot), with gp120to~ as the total gp120 con- 
centration. FLm~  and Ka were fitted using nonlinear regression of 
the Systat Program (Systat Inc., Evanston, IL). On-rates were de- 
termined by plotting -ln(1  -  f) vs. time with slope m (/eo~ + 
kon) x  gp120 (37). Results from off-rate experiments were plotted 
as In (f) vs. time with slope m  -/e,~ (37). Slopes were determined 
using a linear regression program. Note that the soluble recom- 
binant gp120 is monomeric and its binding to soluble CD4 is 
monovalent (data not shown). Our calcuhtions are based on the 
assumption that transmembrane  CD4-gp120 interaction is monova- 
lent as well. 
Graphics.  For computer graphics of the CD4 structure 03), 
a Silicon Graphics IRIS workstation (413/80) was used together 
with the Insight II program (Biosym  Technologies,  San Diego, CA). 
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Ribbon diagram representing CD4 domain 1. ~ strands are labded in cap- 
ital letters (float face strands, open boxes;  back face strands, filled boxes) 
and residues analyzed herein are hbeled with numbers according to 
their position. Residues  that affect  CD4 mAb binding are indicated with 
symbols: Leu3a (O), 19Thy5D7 ([2]), 18T3A9 (A), RFT4 (V), VIT4 
(O), BL4IOT4 (W). 
Results 
Generation and Expression of CD4 Mutant Molecules.  26 in- 
dividual CD4 variants, substituted at 20 distinct amino acid 
positions, were generated by site-directed mutagenesis in order 
to define more precisely the key determinants of HIV gp120 
binding.  As shown in Fig.  1, the mutated residues include 
13 amino  adds located in strands  C',  C",  and D  (residues 
35-62).  Close to the region referred to as the C'C" ridge 
are residues 27 and 29, located in the C strand (Fig. 1). Amino 
adds 77,  81,  and 85 on the F  strand,  and residues  19 and 
89 at the top of strands B  and G, respectively, lie outside 
the C'C" ridge (Fig. 1). Mutant CD4 cDNAs were dectropo- 
rated into the murine T  cell hybridoma MA5.8,  and stable 
transfectants were characterized for surface CD4 expression. 
Compared with peripheral blood T lymphocytes, CD4 trans- 
fectants  expressed  ~10-fold  less  CD4  as judged  by  im- 
munofhorescence (data not shown). This level of expression 
was comparable for individual cell lines transfected with the 
different  CD4 mutants. 
CD4 raAb Binding.  To exclude the possibility that dimin- 
ished HIV gp120 binding capacity was a trivial consequence 
of overall disruption  of conformation in the first CD4 do- 
main,  each mutant was analyzed with a pand of anti-CD4 
mAbs directed at the native domain 1. These anti-CD4 mAbs 
were selected according to published epitope mapping studies 
TIbh  1.  Reactivity of CD4 Mutants with CD4 raAbs 
Mutation  L3a  19Thy  18T3  RFT4  VIT4  BL4  OKT4 
SlOY  CIOD CIDO DOD  DCID ml~  DDD  DC]D 
H27A  1-11-11-I  mid  ODD  DDD  ODD  DOD  DOD 
K35A  ill  Ill  ODD  Ill  00[3 00[3 ODD 
G38A  I-IC]D  DDCI ODD  DOD  00[3 OnE] [3[2]0 
Q40A  GIID DD[-I Dl-]l-11-11-11-I  DDCI CIDO DCID 
F43A  DOE] nDD  mnm  DCID DDD  DDO  DDD 
F43I  IllO  nun  ,,nil DDn  DDD  DOO  DOD 
F43L  DI-II-I  DDI-I [-IDl-1  DI71D l-l[q[-I  [-IDl-I  lql-ID 
F43W  1-11-11-I  1-11-I[-I  mid  DDD  DDD  DDD  DrTr  
F43Y  DDD  mid  mml  DDD  FIOE] DCID ODD 
T45A  OFl[-I  ODD O[-IO ODD OOO O[Z]D OOO 
K46A  OFIO  noo ODD non nOD [qOD O[30 
P48Q  Ol-']O  On[]] ODD DE]C] CIDD 0OO On[]] 
$49V  OOl-I  Ol-lO O[Z]O OO0 OOO OOO DON 
N52A  O[-IO  OOO OOO ODD OOO ODD Ol-lO 
A55V  DOn DOn nOD DOn EIOD OI3E] []]nO 
D56A  OO[-I  [Z]OO ann ooo ooo ooo oDD 
R59A  DDO OOO OOO OOO [-IOD F-IOO DO0 
R59K  OOO Don miid OOO OOO DO0000 
W62Y  0OO nno iRm oo~] [3c]o ooo ODD 
E77Q  DO0 ODD O[-IO FIO[-I ClOD imo oDD 
T81A  O0[-I  ODD O[-IO DO0 l-IFIO DO[Z] ODO 
E85A  O/-lO  [-IOO ODD GOD OO~ GOD OOO 
E85Q  DO0 [-IOO DOD ODD nOD [300 E]OI3 
K29A/ 
E85A F'I[]D  [-][-ID D[-I[-1  HiD  [-1DF'I [-1['-1~ DF'I[-] 
Q89L  I-IDI-I  DFID DDI-I 1-11-11-I  BRR 0[3[3 DI-IO 
Binding of CD4 raAbs to cells expressing CD4 mutants was determined 
by immunofluorescence  and compared with binding of OKT4. Reactivi- 
ty was calculated as follows: {[mutant-FL(mAb) -  mutant-FL(neg)]/ 
[mutant-FL(OKT4)-mutant-FL(neg)]]/[[wt-FL(mAb)-wt-FL(neg)]/ 
[wt-FL(OKT4)-wt-FL(neg)]]; where FL = linear fluorescence  obtained 
with the specified mAb. Symbol code for reactivity is: [:]/qO, 0.8-1; 
mUlE], 0.5-0.8; Rill,  0.2-0.5; Illll no mAb binding. 
(29, 38, 39). Leu3a,  19ThySD7,  18T3Ag,  and RFT4 have 
been mapped to the C'C" ridge; RFT4 also to the C strand; 
and VIT4, and BL4IOT4 to the side of CD4 domain 1 op- 
posite that of the C'C" ridge, mAb OKT4, which binds to 
a membrane proximal domain of CD4, reacted with all mu- 
tants. We used it to determine levels of CD4 expression and 
as a reference to compare reactivity of the other CD4 mAbs. 
As shown in Table 1, each mutant had a distinct binding 
pattern with the panel of anti-CD4 mAbs. None of the mu- 
tants led to loss of the majority of antibody epitopes. The 
binding  of mAbs known  to interact  with  the C'C"  ridge 
was reduced or eliminated by mutations in this region (e.g., 
at positions 35, 43, and 62), but the binding of other mAbs 
interacting with different parts of domain 1 was unaffected. 
Note that  several  mutations,  including  G38A and Q40A, 
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of mAbs. The restricted effect of substitutions  on mAb reac- 
tivity demonstrates that these mutations exert only local effects 
on the structure of CD4 and suggests that the overall con- 
formation of domain 1 is preserved. Based on these results, 
we interpret the effects of surface-exposed mutations to be 
a direct consequence of the mutated residue rather than an 
indirect  effect of disrupting the entire domain. 
These antibody binding experiments contribute additional 
precision to previous mapping of anti-CD4 mAbs. Substitu- 
tions that affect binding of CD4 mAbs are summarized in 
Fig. 1, and their positions are indicated on the model of CD4 
domain 1. Leu3a, 19Thy5D7, and 18T3A9 all interact with 
the C'C" ridge, but their detailed pattern of sensitivity to 
changes in this region is different. Thus, the K35A mutant 
no longer binds Leu3a or 19Thy5DT, but it binds 18T3A9 
with normal affinity. In contrast,  18T3A9 is more sensitive 
to changes at F43, D56, R59, and W62 than either of the 
other two mAbs. These differences probably reflect a combi- 
nation of distinct footprints of antibody contact and different 
kinds of pockets in the antigen combining site. 
Kinetics and Temperature Dependence of CD4-gpl20 Interac- 
tion.  We established conditions for measurement of equi- 
librium affinities and kinetics of  gp120 interaction with wild- 
type and mutant CD4 molecules. As shown in Fig. 2 A, 
binding of gp120 to CD4 expressed on human T lympho- 
cytes was slow at 4~  a plateau was not reached even after 
12 h using 10 nM gp120. The ko~ in this experiment was 
0.46 rain-1  x  #M-t. Furthermore, no substantial dissoci- 
ation of gp120 from CD4 was observed, even after 24 h. In 
contrast,  association  of gp120 with  CD4  occurred more 
quickly at 37~  and binding was complete after 2 h (Fig. 
2 B). Moreover, gp120 almost completely dissociated from 
CD4 at 37~  within 2 h of incubation (Fig. 2 B). The tem- 
perature dependence of CD4-gp120  interaction  noted here 
is consistent with a recent independent analysis (40). Similar 
kinetics for the CD4-gp120  on- and off-reactions were ob- 
served when wt-CD4 transfectants were analyzed at 37~ 
(Fig. 2 C). We note that the level of surface CD4 expression 
was stable after incubation with gp120. These results show 
that equilibrium in the CD4-gp120 interaction can be achieved 
by incubating for several hours at 37~  To verify this asser- 
tion  further,  untreated  CD4  transfectants  and  gp120- 
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Figure 3.  Equilibrium binding of 
CD4-gp120 intmction,  wt-CD4 trans- 
fectants,  either  untreated  (0) or  prein- 
cubated with  20 nM gp120 at 37~ 
for 1 h (@), were  washed and sub- 
sequently incubated with 1.5  nM 
HIVIIIB gp120. Call-bound gp120 
was determined  by immunofluores- 
cence. 
preincubated CD4 transfectants were incubated in parallel at 
37~  with an intermediate concentration of gp120 (1.5 nM) 
for various periods of time. Subsequently, the level of cell- 
bound gp120 was determined. As shown in Fig. 3, similar 
fractions of cell-bound gp120 were observed after 1.5-4 h, 
regardless of whether the experiment was started with gp120- 
loaded or untreated cells. Equilibrium was achieved, with 
similar kinetics, when human CD4 + T cells were analyzed 
(not shown).  Based on these findings, we used incubation 
periods of 8-12 h at 37~  to determine equilibrium affinities 
of mutant CD4 and gp120. 
Analysis of CD4 Mutants for Binding of gpl20 Identifies a 
Key  Hydrophobic Contact and  Several Positively Charged 
Residues.  The affinity of wt-CD4 and CD4 mutants for 
HIVIIIB gp120 was then determined. Representative equi- 
librium binding experiments (Fig. 4 A) and kinetic experi- 
ments (Fig. 4, B and C) obtained with wild-type CD4 and 
mutants H27A, G38A, and Q40A are shown. The summary 
of results obtained on all mutants is tabulated in Table 2. As 
shown in Fig. 4 A,  using cells expressing wt-CD4,  a Kd 
with a mean value of 0.9 nM was determined for HIVIIIB 
gp120. Mutant H27A showed a very similar binding curve 
(Ka  =  1.6 riM); mutant G38A  showed a reduced affinity 
(Ka  =  9.4 nM); and mutant Q40A showed a slightly but 
significantly enhanced affinity (Kd =  0.5 riM). Experiments 
aimed at analyzing the on-reaction for these mutants yielded 
relatively similar time courses for saturation (Fig. 4 B). The 
summary of the binding rate constants listed in Table 2 demon- 
strates that relative to wild-type CD4,  there is no change 
in ken for H27A, a slight reduction for G38A and a two- 
to threefold increase for Q40A. Experiments shown in Fig. 
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Figure 2.  Kinetics of CD4-gpl20 inter- 
action. CD4-gp120 association (0) and dis- 
sociation (0) as determined with human 
T lymphocytes and HIVIIIB gp120 at 4~ 
(A) and 37~  (B), respectively. In associa- 
tion  experiments,  gp120  concentrations 
were 10.0 (A) and 1.0 nM (B), respectively. 
Kinetics for wt-CD4-transfected MAS.8 at 
37~  are shown in C; HIVIIIB gp120 was 
used at 1,5 nM for the association experi- 
ments, Cell-bound gp120 was determined 
by immunofluorescence  and expression of 
CD4 (I-3) in the presence of gp120 by using 
mAb OKT4. 
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H~re 4.  Determin=tion of CD4-gpl20 
.~.ities. Eqnih~riam  bindin  s (.4), on-rate 
(/3), and o~-.= (C) ~'l~im~ts l~e'~med 
with wt-CD4 (m) and mutants H27A (O), 
G38A ([]), and Q40A (A), and HIVIIIB 
gp120. The highest gp120 concentration in 
the equilibrium binding shown in A was 
75 aM. Specific fluo1~cence of gpl20 at 
saturation was taken as unity. Concentra- 
tions of gp120 used in on-rate experiments 
(B) were: wt, 3 aM; H27A, 3 aM; G38A, 
15 aM; Q40A, 0.5 nM. Note that these 
latter experiments were performed at a concentration of g,  p120 estimated to be three times the Kd for each mutant as determined in the equilibrium 
experiments; hence, different gp120 concentrations were used in each case. Thus, the curves shown do not directly represent the association rate constant. 
4 C demonstrate that the dissociation rate was almost un- 
changed for H27A, increased by twofold for G38A and re- 
duced by twofold for Q40A. Note that the determinations 
of Ka by equilibrium and kinetic experiments are in reason- 
able agreement for these and other mutants. 
Substitutions at positions 35, 43, and 62 had the most pro- 
nounced effects on CD4 affinity for gp120. As shown in Fig. 
5 A  and Table 2, mutants K35A and W62Y have dissocia- 
tion constants for gp120 of 45 and 152 raM, respectively, and 
500 nM gp120 was required to achieve 50% saturation when 
mutant F43A was utilized. 5-20-fold decreased affinities  were 
observed for mutants K46A, P48Q,  $49V, IL59A, and for 
the double mutant K29A/E85A (Table 2). Because substitu- 
tion E85A showed no effect on g'p120 binding, reduced aff~ty 
of mutant K29A/E85A can probably be interpreted as an 
effect of replacing Lys29 with Ala. In addition to mutant 
Q40A, slightly enhanced affinities (Kd of 0.5 riM) were also 
observed for mutants T45A and R59K (Table 2). Fig. 6 illus- 
trates  the position of CD4 residues affecting HIV gp120 
binding. All other mutations shown in Table 2, including 
substitutions at positions 77, 81, and 85, showed no effect 
on gp120 binding. 
A  Critical  golefor Phe#3 in HIVgp120 Binding.  The above 
results show that F43 is the most critical of all the residues 
tested with regard to HIV gp120 binding. To explore further 
the requirements of the hydrophobic residue at this position, 
Phe 43 was substituted with four other hydrophobic amino 
acids. As shown in Fig. 5 B, substitution of Ile at position 
43 resulted in a ',~500-fold loss in gp120 affinity; Trp and 
Tyr substitutions  gave 15-30-fold decreases; and Leu yidded 
only a twofold reduction. Thus, the chemical structure of 
the side chain at position 43 (Fig. 5 C) dramatically influences 
gp120 binding. 
Reduced A.~nities of CD4 Mutants for HIV gp120 Are Pri. 
raarily Due to an Increase in kog.  Kinetic experiments de- 
scribed in Fig. 4, B and C were performed with all mutants 
except for F43A, F43I, and W62Y,  where the low ai~nity 
would have required use of excessively high concentrations 
of gp120. Mutants with reduced equilibrium binding con- 
stants for gp120 showed changes predominantly in the dis- 
sociation rate constants  (Table 2). For example, the ko~ for 
K35A was 173 min -1  x  10 -3 compared with 12.5 rain -t 
x  10-3 for wt-CD4. In some cases, however, such as mu- 
tants K35A,  F43Y, K46A,  and R59A, a decreased associa- 
tion rate was also observed when compared to wt-CD4. It 
should be mentioned that like wt-CD4, none of the mutants 
showed any dissociation of bound gp120 at 4~  within a 
period of 2 h. Kinetics of mutants F43A, F43I, and W62Y 
were not analyzed at 37~  due to their low aff~ty. Neverthe- 
less, dissociation of bound gp120 studied at 25~  showed 
off-rates in the order F43A  >  F43I  >  W62Y  >  wt (not 
shown).  Q40A  showed  the most marked increase in  ko, 
(16.5 min -1 vs.  6.1 min -t  x  ~M -t for wt-CD4). 
Mutations in CD4 Affect Binding of gpl2O from More than 
One HIV Stain.  To determine whether or not the same 
residues in CD4 inSuence the binding of diverse HIV strains, 
CD4 mutants with reduced affnfities  for HIVIIIB gp120 were 
tested in equilibrium  binding experiments for their ability 
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Figure 5.  Affinity of CD4 mutants for 
HIVIIIB 87120. Equilibrium binding m- 
periments with wt-CD4 (O) and mutants 
K35A (D), F43A (Q), W62Y (A), F43L 
(V),  F43W (A), F43Y  (~),  and F43I 
(~). The highest g10120 concentration in 
this experiment was 500 aM. Fluorescence 
of gp120 at saturation  was ~trapohted for 
mutants F43A and F43I according to thdr 
level of CD4 expression and the ratio of 
CD4- vs. gpl20-specific fluorescence as ob- 
tained for wt and other mutants at satu- 
ration. 
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Mutation  kon 
Kinetic experiments 
Equilibrium 
koa  koa/kon  conditions  (Kd) 
min -1  x  /,tM  -1  rain -~  ￿  10 -3  nM  nM 
wt  6.1  _+  2.4  12,5  _+  1.2  2.0  0.9  _+  0.3 
S19Y  5.9  13.1  2.2  1.2 
H27A  5.5  13,3  2.4  1.6 
K35A  1.8  173.3  98  45 
G38A  3.2  27.7  8.7  9.4 
Q40A  16.5  5.8  0.4  0.5 
F43A  ND  ND  ND  500 
F43I  ND  ND  ND  500 
F43L  5.9  21.6  3.7  2.5 
F43W  3.9  76.9  20  16 
F43Y  1.7  53.3  32  32 
T45A  7.7  9.6  1.3  0.6 
K46A  2.0  33.0  16  19 
P48Q  4.5  34.6  7.6  4.5 
$49V  3.6  46.2  13  13 
N52A  5.7  10.2  1.8  0.8 
A55V  5.0  18.2  3.6  2.4 
D56A  4.3  12.2  2.9  1.6 
R59A  2.4  26.6  11  7.9 
R59K  7.1  9.5  1.3  0.6 
W62Y  ND  ND  ND  152 
E77Q  8.9  11.6  1.3  1.3 
T81A  3.5  18.2  5.2  1.5 
E85A  7.2  16.9  2.4  1.3 
E85Q  3,6  16.9  4.7  1.5 
K29A/E85A  3.7  49.5  13  6.7 
Q89L  7.3  12.8  1.8  1.2 
to bind gpl20 derived from the structurally distinct HIV strain 
SF2.  The affinity of wt-CD4 for SF2  gpl20 is more than 
one order of magnitude lower than for HIVIIIB gp120 (Ka 
=  20 vs. 0.9 nM). As shown in Table 3, all mutations with 
reduced affinities for HIVIIIB gp120 showed diminished affini- 
ties also for SF2 gp120. Moreover,  for each individual mu- 
tant the change in affinity  for SF2 gp120 was comparable 
to the change observed with HIVIIIB gp120 (Table 3). 
Discussion 
We have established experimental conditions for measuring 
the affinity of gp120 and mutant CD4 at equilibrium, as well 
as for determining the rate constants for association and dis- 
sociation. The kinetics are strongly temperature dependent. 
The rate of  dissociation is negligible at 4~  and it was there- 
fore necessary to perform the studies at 37~  in order to achieve 
equilibrium. CD4 is not rapidly endocytosed when expressed 
on the surface of lymphoid ceils (41),  and we could deter- 
mine gp120 binding curves over an 8-12-h period in stable 
murine T cell line transfectants. Most previous experiments 
on gp120 binding to expressed mutants of CD4 were per- 
formed at lower temperature (12, 28, 30-32), and they were 
therefore primarily measurements of relative on-rates rather 
than of equilibrium affinities.  The properties of the K35A 
mutant are a useful illustration: the effect of the change on 
the rate of CD4-gpl20 association is much smaller than its 
effect on dissociation. A measurement sensitive only to kon 
would have shown a small change in apparent binding.  In 
other cases, there are changes in both association and dissoci- 
ation rate constants, but only the equilibrium binding mea- 
surements, which take both into account, reveal the full effect 
of the substitution. 
512  The CD4 Binding Site for HIV gpl20 Table 3.  Mutant Reactivity with SF2 gpl20 
Mutant 
Fold decrease  Fold decrease 
Ka for  of a~nity for  of af~nity for 
SF2 gp120  SF2 gp120  HIVIIIB gp120 
nM 
wt  20  1  1 
K35A  1,000  50  50 
G38A  120  6  10 
F43A  nsb  ND  550 
F43W  400  20  18 
K46A  350  17  21 
P48Q  140  7  5 
$49V  200  10  14 
R59A  200  10  9 
W62Y  >1,000  ~>50  169 
K29A/E85A  200  10  7 
Af~nities  for SF2 gp120 were determined  using  equilibrium  binding  con- 
ditions, nsb, no specific  binding. 
The most striking effects uncovered here are those associated 
with substitution at Phe43. The exposed hydrophobic side 
chain (Fig. 6) is an unusual feature of CD4, and additional 
studies from our laboratory suggest that it is important for 
the normal function of CD4 in binding to dass II MHC 
molecules (Moebius et al., manuscript submitted for publi- 
cation). We observe a graded series of changes when other 
hydrophobic side chains are introduced at this position. Sub- 
stituting tyrosine or tryptophan introduces a polar atom and 
increases side chain volume, leading to 30-fold and 15-fold 
decreases in affinity, respectively, but complete removal of 
the aromatic group in the F43A mutant leads to an even more 
pronounced effect  (•500-fold).  A  leucine at  position 43 
produces a very modestly reduced affinity, but isoleucine is 
as unfavorable  as alanine.  Not only must the residue at 43 
have a pronounced hydrophobic character, it must also have 
a particular shape. The simplest explanation is that a pocket 
on gp120 normally accommodates Phe43 and that this pocket 
can admit a leucine side chain but not a 3-branched isolen- 
cine. Several mAbs, including Leu3a, have the same strong 
preference  (Table 1). 
Removal of any of four positively charged side chains (K29, 
K35, K46, and R59) in the vicinity ofF43 also reduces affufity 
for gp120 (Fig. 6). The strongest effect (50-fold) is obtained 
with mutant K35A. Preserving the charge at position 59 in 
CD4 by replacing arginine with lysine actually increases affinity 
for gp120 by a small amount. The distances between the posi- 
tive ch~ges and the C/~ of Phe43 are 9.35, 9.81,  11.32, and 
19.57 A  for IL59, K35, K46, and K29, respectively.  The 
importance of K35 has not been noticed in most previous 
mutagenesis studies, perhaps because its influence is largely 
on the rate of dissociation. Recent experiments with human/ 
rat  CD4 chimeras show that in order to be a functional 
receptor,  the  molecule must  have  a  human  sequence  at 
K35 (where rat CD4 has threonine), consistent with our 
results (42). 
Substituting alanine for glutamine at position 40 or for 
threonine at position 45 results in a small enhancement of 
gp120 binding. Both these side chains lie on the molecular 
surface dose to Phe43 (Fig. 6), and it is plausible to suppose 
that they interfere slightly with the correct fit of gpl20 to 
CD4. The added methyl group in the G38A variant also ap- 
pears to interfere, leading to a 5-10-fold decrease in affinity 
for gp120. We conclude that surface topography in the neigh- 
borhoo  d of Phe43, including the entire C'C" turn from res- 
idue 38 to 45, can influence the gp120 interaction. 
This conclusion is reinforced by the even more substantial 
effect of the W62Y substitution. Most of the tryptophanyl 
side chain is buried beneath the C'C" turn, and its bulk is 
probably critical for the way the turn projects from the edge 
of the CD4 molecule (Fig. 6). We chose tyrosine as a substi- 
tution in order to preserve the hydrophobic character of this 
residue  and  to  maintain  a  hydrogen-bonding function. 
Nonetheless, the modest reduction in side chain volume and 
the slight repositioning of a hydrogen-bonding group (the 
phenolic hydroxyl of tyrosine lies ,x,2 A  farther from C/3 
than does the indole nitrogen of tryptophan) leads to a 150- 
fold loss of affinity. 
The properties of several of our mutants also demonstrate 
that the gp120 interaction  is sensitive  to the conformation 
of the "lower" part of the C" ridge (the C" D corner). P48Q 
and $49V both have somewhat reduced affinity for gp120. 
Proline 48 lies at the edge of this CD4 molecule, at the end 
of the C" strand, and serine 49 points into the C" D corner 
(Fig. 6). Its side chain hydroxyl is hydrogen bonded to a bu- 
fled water.  The valine substitution may alter the shape of 
the C" D  corner by eliminating a hydrogen-bonding func- 
tion. The slightly lower affinity of A55V, which points into 
the C" D  corner from the opposite face of domain 1, may 
also be due to a local distortion in this part of the molecule. 
The results and conclusions summarized here are largely 
consistent with previous binding studies, which demonstrate 
an effect on the gp120 interaction from substitutions at res- 
idue 29, 40, 43, 46, 48, 49, 59, or 62 (31, 32, 43, 44). Like- 
wise, the lack of effect from a substitution at 19, 27, 56, or 
89 is consistent with the literature (31, 32, 43, 44). In con- 
trast, we do not observe any change in affinity resulting from 
mutation of 52, 77, 81, or 85, all of which were reported 
to influence gp120 binding (32). The basis of the disparity 
is unclear, but a third study also reports no effects from sub- 
stitutions at 81 and 85 (44).  Our findings that mutations 
at these charged (E77 and E85) and polar ($19, T81, and Q89) 
residues show unaffected gp120 affinity do not support the 
notion that residues spatially well removed from the C'C" 
ridge contribute critically to the gp120 interaction. Residues 
near the C'C" ridge that are not included in this study have 
been examined qualitatively in other's work. Alterations of 
surface residues N30, $31, N32, Q33, K50, D53, K58, or 
$60 have no effect on gp120 binding (31, 32). Changing bu- 
fled residue 136, L37, L51, K54, or $57 produces an overall 
513  Moebius  et al. Figure 6.  Illustration of the gp120 binding site. Stereo views of (A) space-falling model of CD4 domains 1 and 2, and (B) a-carbon  trace model 
of CD4 domain 1 according to the atomic structure of CD4 (33). Charged residues involved in gp120 binding are shown in red (K29, K35, K46, 
and R59). The hydrophobic residue (F43) involved in gp120 binding is shown in yellow. The buried residue that affects gp120 binding by altering 
the C'C" ridge (W62) and the buried ($49) and exposed (P48) residues altering the C"D turn are shown in green. Amino acids (Q40 and T45) whose 
mutation to alanine enhanced gp120 binding are shown in dark blue. 
loss of conformational stability in domain 1, as deduced from 
the effect of reactivity with a varity of CD4 mAbs (32). Mu- 
tations at G41, L44, and G47 are reported to decrease affinity 
for gp120 (31, 32), and examination of the modal shows that 
the changes in question would be expected to perturb the 
conformation of the C'C" turn or the C"D corner. For ex- 
ample, leucine 44 packs against tryptophan 62 and helps de- 
termine the projecting conformation of phenylalanine 43. The 
514  The CD4 Binding Site for HIV gp120 Q40P and T45P mutations, reported to interfere with gp120 
binding (43), would also be expected to alter the C'C" turn. 
We  conclude  that  the  principal  determinant  of gp120 
binding is a continuous region on the surface of domain  1 
covering  ,v900 A  2 of accessible surface.  This  site contains 
Phe43 near its center partially surrounded by positiwly charged 
residues Lys29, Lys35, Lys46, and Arg59.  The importance 
of positively charged residues in the vicinity of Phe43 is in- 
teresting in view of a previous report where three negatively 
charged residues in gp120 have been demonstrated to be crit- 
ical for binding to CD4 (45). Two of the three residues are 
conserved not only among HIV-1 isolates, but also in HIV-2 
and in SIV strains.  The contact between the viral glycopro- 
tein and its receptor might  therefore include a set of ionic 
interactions  flanking  a central  hydrophobic patch. 
The binding site on CD4 for its normal interaction with 
class II MHC molecules is more complex than  the site for 
gp120 (12, 43, 46). It includes several other parts of the mo- 
lecular surface in domains 1 and 2, in addition to the C'C" 
ridge. It is striking, however, that when the same CD4 mu- 
tations analyzed here were examined for their capacity to bind 
class  II  MHC  molecules,  similar  effects  were  observed 
(Moebius et al., manuscript  submitted for publication).  In 
particular,  the alterations that reduce gp120 binding (K35A, 
F43A, K46A, $49V,  R59A, and W62Y) also diminish  ro- 
sette formation between CD4-transfected COS-1 cells  and 
class  II MHC-expressing  B  cells.  A  surface region with  a 
projecting hydrophobic side chain (Phe43) and adjacent posi- 
tively charged residues thus also appears to be important for 
the class II MHC interaction. The overlap ofHIV gp120 and 
class II binding sites requires that development of receptor- 
based HIV inhibitors avoids drugs with immunosuppressive 
properties. Our detailed analysis of the contribution of residues 
in CD4 domain 1 to HIV gp120 binding gives a quantitative 
assessment of key components in the virus binding site, with 
such developments in mind. 
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